Review

Epigenetic mechanisms driving tumor supportive microenvironment differentiation and function: a role in cancer therapy?

UMR _S 1236, Université de Rennes 1, INSERM, Établissement français du sang (EFS) Bretagne, Rennes, France

Laboratoire Suivi Immunologique des Thérapeutiques Innovantes (SITI), Centre Hospitalier Universitaires de Rennes, Rennes, France

Search for more papers by this author

David Roulois

*Author for correspondence: Tel.: +33 0 2 23 23 46 99;

E-mail Address: David.roulois@univ-rennes1.fr

https://orcid.org/0000-0002-8966-0608

UMR _S 1236, Université de Rennes 1, INSERM, Établissement français du sang (EFS) Bretagne, Rennes, France

Niches & Epigenetics of Tumors from Cancéropole Grand Ouest, France

Search for more papers by this author

Published Online:18 Dec 2019https://doi.org/10.2217/epi-2019-0165

View article

Abstract

The tumor microenvironment (TME) plays a central role in tumor development and drug resistance. Within TME, the stromal cell subset, called cancer-associated fibroblasts, is a heterogeneous population originating from poorly characterized precursors. Since cancer-associated fibroblasts do not acquire somatic mutations, other mechanisms like epigenetic regulation, could be involved in the development of these cells and in the acquisition of tumor supportive phenotypes. Moreover, such epigenetic modulations have been correlated to the emergence of an immunosuppressive microenvironment facilitating tumor evasion. These findings underline the need to deepen our knowledge on epigenetic mechanisms driving TME development and function, and to understand the impact of epigenetic drugs that could be used in future to target both tumor cells and their TME.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Slack JMW. Conrad Hal Waddington: the last Renaissance biologist? Nat. Rev. Genet. 3, 889–895 (2002) Nature Publishing Group.
Medline CASGoogle Scholar
2. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 128(4), 635–638 (2007).
Medline CASGoogle Scholar
3. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17(8), 487–500 (2016).
Medline CASGoogle Scholar
4. Dzobo K. Epigenomics-guided drug development: recent advances in solving the cancer treatment “jigsaw puzzle”. OMICS 23(2), 70–85 (2019).
Medline CASGoogle Scholar
5. Esteller M. Epigenetic drugs: more than meets the eye. Epigenetics 12(5), 307–307 (2017).
MedlineGoogle Scholar
6. Schübeler D. Function and information content of DNA methylation. Nature 517(7534), 321–326 (2015).
Medline CASGoogle Scholar
7. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 12(1), 7–18 (2011).
MedlineGoogle Scholar
8. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693–705 (2007).
Medline CASGoogle Scholar
9. Michalak EM, Burr ML, Bannister AJ, Dawson MA. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat. Rev. Mol. Cell Biol. 150(6), 12–17 (2019).
Google Scholar
10. Ambros V. The functions of animal microRNAs. Nature 431(7006), 350–355 (2004).
Medline CASGoogle Scholar
11. Fernandes JCR, Acuña SM, Aoki JI, Floeter-Winter LM, Muxel SM. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Noncoding RNA 5(1), 17 (2019).
Medline CASGoogle Scholar
12. Sun Y-C, Wang Y-Y, Ge W, Cheng S-F, Dyce PW, Shen W. Epigenetic regulation during the differentiation of stem cells to germ cells. Oncotarget 8(34), 57836–57844 (2017).
MedlineGoogle Scholar
13. V Subramaniam A, Yehya AHS, Cheng WK, Wang X, Oon CE. Epigenetics: the master control of endothelial cell fate in cancer. Life Sci. 232, 116652 (2019).
Medline CASGoogle Scholar
14. Jambhekar A, Dhall A, Shi Y. Roles and regulation of histone methylation in animal development. Nat. Rev. Mol. Cell Biol. 403, 1–17 (2019).
Google Scholar
15. Du H, Che G. Genetic alterations and epigenetic alterations of cancer-associated fibroblasts. Oncol. Lett. 13(1), 3–12 (2017).
Medline CASGoogle Scholar
16. Liu M, Zhou J, Chen Z, Cheng AS-L. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. J. Pathol. 241(1), 10–24 (2017). •• Underlines the impact of epigenetic control on the tumor microenvironment and in particular myeloid compartment.
MedlineGoogle Scholar
17. Marks DL, Olson RL, Fernandez-Zapico ME. Epigenetic control of the tumor microenvironment. 8(12), 1671–1687 (2016).
Google Scholar
18. Pidsley R, Lawrence MG, Zotenko E et al. Enduring epigenetic landmarks define the cancer microenvironment. Genome Res. 28(5), 625–638 (2018).
Medline CASGoogle Scholar
19. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22(1), 9–20 (2012).
Medline CASGoogle Scholar
20. Boice M, Salloum D, Mourcin F et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell 167(2), 405–418.e13 (2016).
Medline CASGoogle Scholar
21. Pasqualucci L. Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunol. Rev. 288(1), 240–261 (2019).
Medline CASGoogle Scholar
22. Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood 131(6), 595–604 (2018).
Medline CASGoogle Scholar
23. Martignoles J-A, Delhommeau F, Hirsch P. Genetic hierarchy of acute myeloid leukemia: from clonal hematopoiesis to molecular residual disease. Int. J. Mol. Sci. 19(12), 3850 (2018).
Google Scholar
24. Jones PA, Laird PW. Cancer-epigenetics comes of age. Nat. Genet. 21(2), 163–167 (1999).
Medline CASGoogle Scholar
25. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683–692 (2007).
Medline CASGoogle Scholar
26. Park W-Y, Hong B-J, Lee J, Choi C, Kim M-Y. H3K27 demethylase JMJD3 Employs the NF-κB and BMP signaling pathways to modulate the tumor microenvironment and promote melanoma progression and metastasis. Cancer Res. 76(1), 161–170 (2016).
Medline CASGoogle Scholar
27. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3), 309–322 (2012).
Medline CASGoogle Scholar
28. Hirata E, Sahai E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb. Perspect. Med. 7(7), a026781 (2017).
MedlineGoogle Scholar
29. Senthebane DA, Jonker T, Rowe A et al. The role of tumor microenvironment in chemoresistance: 3d extracellular matrices as accomplices. Int. J. Mol. Sci. Page 3850 19(10), 2861 (2018).
Google Scholar
30. Senthebane DA, Rowe A, Thomford NE et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int. J. Mol. Sci. Page 3850. 18(7), 1586 (2017).
Google Scholar
31. Guilloton F, Caron G, Ménard C et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119(11), 2556–2567 (2012).
Medline CASGoogle Scholar
32. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer 125(7), 1640–1648 (2009).
Medline CASGoogle Scholar
33. Mamrot J, Balachandran S, Steele EJ, Lindley RA. Molecular model linking Th2 polarized M2 tumour-associated macrophages with deaminase-mediated cancer progression mutation signatures. Scand. J. Immunol. 89(5), e12760 (2019).
MedlineGoogle Scholar
34. Wang D, Yang L, Yue D et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett. 452, 244–253 (2019).
Medline CASGoogle Scholar
35. Mariathasan S, Turley SJ, Nickles D et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693), 544–548 (2018).
Medline CASGoogle Scholar
36. Kather JN, Suarez-Carmona M, Charoentong P et al. Topography of cancer-associated immune cells in human solid tumors. Elife 7, 16878 (2018).
Google Scholar
37. Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy 8(6), 705–719 (2016).
CASGoogle Scholar
38. Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 22, 1 (2019).
Google Scholar
39. Toor SM, Sasidharan Nair V, Decock J, Elkord E. Immune checkpoints in the tumor microenvironment. Semin. Cancer Biol. 19 (2019). S1044-579X(19)30123-3
Google Scholar
40. Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin. Cancer Biol. 25, 23–32 (2014).
Medline CASGoogle Scholar
41. Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front. Immunol. 10, 1835 (2019).
Medline CASGoogle Scholar
42. Givel A-M, Kieffer Y, Scholer-Dahirel A et al. miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat. Commun. 9(1), 1056 (2018). • Shows cancer-associated fibroblasts (CAFs) heterogeneity in breast cancers and the impact of a miR, miR-141/200a, on the immunosuppressive properties of CAFs with CXCL12b secretion.
MedlineGoogle Scholar
43. Costa A, Kieffer Y, Scholer-Dahirel A et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33(3), 463–479.e10 (2018).
Medline CASGoogle Scholar
44. Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9(1), 4692 (2018).
MedlineGoogle Scholar
45. Madar S, Goldstein I, Rotter V. “Cancer associated fibroblasts” – more than meets the eye. Trends Mol. Med. 19(8), 447–453 (2013).
Medline CASGoogle Scholar
46. Chang JE, Turley SJ. Stromal infrastructure of the lymph node and coordination of immunity. Trends Immunol. 36(1), 30–39 (2015).
Medline CASGoogle Scholar
47. Colbeck EJ, Ager A, Gallimore A, Jones GW. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front. Immunol. 8, 867 (2017).
MedlineGoogle Scholar
48. Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4), 782–795 (2013).
Medline CASGoogle Scholar
49. Riedel A, Shorthouse D, Haas L, Hall BA, Shields J. Tumor-induced stromal reprogramming drives lymph node transformation. Nat. Immunol. 17(9), 1118–1127 (2016). •• This transcriptomic study during tumorigenesis shows a conversion of stromal cells populations in CAFs-like cells in mice models.
Medline CASGoogle Scholar
50. Pandey S, Mourcin F, Marchand T et al. IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood 129(18), 2507–2518 (2017).
Medline CASGoogle Scholar
51. Grégoire M, Guilloton F, Pangault C et al. Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. Oncotarget 6(18), 16471–16487 (2015).
MedlineGoogle Scholar
52. Mathot P, Grandin M, Devailly G et al. DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironment. Oncogenesis 6(10), e390 (2017).
Medline CASGoogle Scholar
53. Le Jiang, Gonda TA, Gamble MV et al. Global Hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res. 68(23), 9900–9908 (2008).
MedlineGoogle Scholar
54. Ling E, Ringel A, Sigal-Batikoff I et al. Human colorectal cancer stage-dependent global DNA hypomethylation of cancer-associated fibroblasts. Anticancer Res. 36(9), 4503–4507 (2016).
Medline CASGoogle Scholar
55. Vizoso M, Puig M, Carmona FJ et al. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis 36(12), 1453–1463 (2015).
Medline CASGoogle Scholar
56. Zeisberg EM, Zeisberg M. The role of promoter hypermethylation in fibroblast activation and fibrogenesis. J. Pathol. 229(2), 264–273 (2013).
Medline CASGoogle Scholar
57. Albrengues J, Bertero T, Grasset E et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat. Commun. 6(1), 10204 (2015). • Demonstrates the role of local hypermethylation in CAFs phenotype in breast cancers.
Medline CASGoogle Scholar
58. Bechtel W, McGoohan S, Zeisberg EM et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16(5), 544–550 (2010).
Medline CASGoogle Scholar
59. Mishra R, Haldar S, Placencio V et al. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J. Clin. Invest. 128(10), 4472–4484 (2018).
MedlineGoogle Scholar
60. Al-Kharashi LA, Al-Mohanna FH, Tulbah A, Aboussekhra A. The DNA methyl-transferase protein DNMT1 enhances tumor-promoting properties of breast stromal fibroblasts. Oncotarget 9(2), 2329–2343 (2018).
MedlineGoogle Scholar
61. Li A, Chen P, Leng Y, Kang J. Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. Oncogene 37(45), 5952–5966 (2018).
Medline CASGoogle Scholar
62. Garcia-Gomez A, Rodríguez-Ubreva J, Ballestar E. Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment. Clin. Immunol. 196, 64–71 (2018).
Medline CASGoogle Scholar
63. Kim DJ, Dunleavey JM, Xiao L et al. Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Br. J. Cancer 118(10), 1359–1368 (2018).
Medline CASGoogle Scholar
64. Kumar V, Donthireddy L, Marvel D et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32(5), 654–668.e5 (2017).
Medline CASGoogle Scholar
65. Kim DE, Procopio M-G, Ghosh S et al. Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation. J. Exp. Med. 214(8), 2349–2368 (2017).
Medline CASGoogle Scholar
66. Maeda M, Takeshima H, Iida N et al. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3. Gut gutjnl–2018–317645 (2019).
MedlineGoogle Scholar
67. Zong Y, Huang J, Sankarasharma D et al. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc. Natl Acad. Sci. USA 109(50), E3395–3404 (2012).
Medline CASGoogle Scholar
68. Xu L, Deng Q, Pan Y et al. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression. Int. J. Mol. Med. 33(1), 91–96 (2014).
MedlineGoogle Scholar
69. Kaukonen R, Mai A, Georgiadou M et al. Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. Nat. Commun. 7(1), 12237 (2016).
Medline CASGoogle Scholar
70. Schoepp M, Ströse AJ, Haier J. Dysregulation of miRNA expression in cancer associated fibroblasts (CAFs) and its consequences on the tumor microenvironment. Cancers (Basel) 9(6), 54 (2017).
Google Scholar
71. Musumeci M, Coppola V, Addario A et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 30(41), 4231–4242 (2011).
Medline CASGoogle Scholar
72. Josson S, Gururajan M, Sung SY et al. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene 34(21), 2690–2699 (2015).
Medline CASGoogle Scholar
73. Batista L, Bourachot B, Mateescu B, Reyal F, Mechta-Grigoriou F. Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through. Nat. Commun. 7(1), 8959 (2016).
Medline CASGoogle Scholar
74. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression – implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356–371 (2019).
Medline CASGoogle Scholar
75. Safari E, Ghorghanlu S, Ahmadi-Khiavi H, Mehranfar S, Rezaei R, Motallebnezhad M. Myeloid-derived suppressor cells and tumor: current knowledge and future perspectives. J. Cell. Physiol. 117(1), 7021 (2018).
Google Scholar
76. Zhang C, Wang S, Liu Y, Yang C. Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer. Oncotarget 7(35), 57452–57463 (2016).
MedlineGoogle Scholar
77. Heine A, Held SAE, Schulte-Schrepping J et al. Generation and functional characterization of MDSC-like cells. Oncoimmunology 6(4), e1295203 (2017).
MedlineGoogle Scholar
78. Lal G, Zhang N, van der Touw W et al. Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation. J. Immunol. 182(1), 259–273 (2009).
Medline CASGoogle Scholar
79. Rodríguez-Ubreva J, Català-Moll F, Obermajer N et al. Prostaglandin E2 leads to the acquisition of DNMT3A-dependent tolerogenic functions in human myeloid-derived suppressor cells. Cell Rep. 21(1), 154–167 (2017).
Medline CASGoogle Scholar
80. Sido JM, Yang X, Nagarkatti PS, Nagarkatti M. Δ9-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8. J. Leukoc. Biol. 97(4), 677–688 (2015).
Medline CASGoogle Scholar
81. Sido JM, Nagarkatti PS, Nagarkatti M. Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells. J. Leukoc. Biol. 98(3), 435–447 (2015).
Medline CASGoogle Scholar
82. Sahakian E, Powers JJ, Chen J et al. Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol. Immunol. 63(2), 579–585 (2015).
Medline CASGoogle Scholar
83. Youn J-I, Kumar V, Collazo M et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 14(3), 211–220 (2013).
Medline CASGoogle Scholar
84. Redd PS, Ibrahim ML, Klement JD et al. SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells. Cancer Res. 77(11), 2834–2843 (2017).
Medline CASGoogle Scholar
85. Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577), 249–253 (2015). • The epigenetic silencing of EZH2 and DNA methylation in TH1 cells allow re-expression of CXCL9 and CXCL10 and reduce tumor immunosuppression.
Medline CASGoogle Scholar
86. Nagarsheth N, Peng D, Kryczek I et al. PRC2 epigenetically silences Th1-Type chemokines to suppress effector T-Cell trafficking in colon cancer. Cancer Res. 76(2), 275–282 (2016).
Medline CASGoogle Scholar
87. Guo X, Qiu W, Wang J et al. Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways. Int. J. Cancer 144, 3111–3126 ijc.32052 (2018).
Google Scholar
88. Guo X, Qiu W, Liu Q et al. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/ Pten Pathways. Oncogene 37(31), 4239–4259 (2018).
Medline CASGoogle Scholar
89. Huber V, Vallacchi V, Fleming V et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128(12), 5505–5516 (2018).
MedlineGoogle Scholar
90. Zhou J, Li X, Wu X et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol. Res. 6(12), 1578–1592 (2018).
Medline CASGoogle Scholar
91. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5(1), 37–50 (2006).
Medline CASGoogle Scholar
92. Gherardini L, Sharma A, Capobianco E, Cinti C. Targeting cancer with Epi-drugs: a precision medicine perspective. Curr. Pharm. Biotechnol. 17(10), 856–865 (2016).
Medline CASGoogle Scholar
93. Roulois D, Loo Yau H, Singhania R et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5), 961–973 (2015). •• Demonstrates the decreasing of colorectal cancers cells proliferation by DNA-demethylating agents which induce a viral mimicry response.
Medline CASGoogle Scholar
94. Chiappinelli KB, Strissel PL, Desrichard A et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5), 974–986 (2015).
Medline CASGoogle Scholar
95. Goswami S, Apostolou I, Zhang J et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Invest. 128(9), 3813–3818 (2018).
MedlineGoogle Scholar
96. Stone ML, Chiappinelli KB, Li H et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl Acad. Sci. USA 114(51), E10981–E10990 (2017).
Medline CASGoogle Scholar
97. Christmas BJ, Rafie CI, Hopkins AC et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol. Res. 6(12), 1561–1577 (2018).
Medline CASGoogle Scholar
98. Briere D, Sudhakar N, Woods DM et al. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol. Immunother. 67(3), 381–392 (2018).
Medline CASGoogle Scholar
99. Yamamoto K, Tateishi K, Kudo Y et al. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Oncotarget 7(38), 61469–61484 (2016).
MedlineGoogle Scholar
100. Issa J-PJ, Kantarjian HM. Targeting DNA methylation. Clin. Cancer Res. 15(12), 3938–3946 (2009).
Medline CASGoogle Scholar
101. Zhao H, Ning S, Nolley R et al. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin. Epigenetics 9(1), 4 (2017).
MedlineGoogle Scholar
102. Ghoneim HE, Fan Y, Moustaki A et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T Cell rejuvenation. Cell 170(1), 142–157.e19 (2017).
Medline CASGoogle Scholar
103. Terracina KP, Graham LJ, Payne KK et al. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol. Immunother. 65(9), 1061–1073 (2016).
Medline CASGoogle Scholar
104. Mikyšková R, Indrová M, Vlková V et al. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J. Leukoc. Biol. 95(5), 743–753 (2014).
MedlineGoogle Scholar
105. Sala L, Franco-Valls H, Stanisavljevic J et al. Abrogation of myofibroblast activities in metastasis and fibrosis by methyltransferase inhibition. Int. J. Cancer 19, 1423 (2019).
Google Scholar
106. Lee S, Kim H-S, Roh K-H et al. DNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells. Sci. Rep. 5, 8020 (2015).
Medline CASGoogle Scholar
107. Huang S, Wang Z, Zhou J et al. EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 79, 2009–2020 (2019).
Medline CASGoogle Scholar
108. Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J. Leukoc. Biol. 91(5), 701–709 (2012).
Medline CASGoogle Scholar
109. Reddy P. Editorial: HDAC inhibition begets more MDSCs. J. Leukoc. Biol. 91(5), 679–681 (2012).
Medline CASGoogle Scholar
110. Tao R, de Zoeten EF, Ozkaynak E et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13(11), 1299–1307 (2007).
Medline CASGoogle Scholar
111. Doñas C, Fritz M, Manríquez V et al. Trichostatin A promotes the generation and suppressive functions of regulatory T cells. Clin. Dev. Immunol. 2013(67), 679804–679808 (2013).
MedlineGoogle Scholar
112. Akimova T, Ge G, Golovina T et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin. Immunol. 136(3), 348–363 (2010).
Medline CASGoogle Scholar
113. Nguyen AH, Elliott IA, Wu N et al. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Oncotarget 8(12), 19074–19088 (2017).
MedlineGoogle Scholar
114. Pazolli E, Alspach E, Milczarek A, Prior J, Piwnica-Worms D, Stewart SA. Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Res. 72(9), 2251–2261 (2012).
Medline CASGoogle Scholar
115. Cramer SA, Adjei IM, Labhasetwar V. Advancements in the delivery of epigenetic drugs. Expert Opin. Drug Deliv. 12(9), 1501–1512 (2015).
MedlineGoogle Scholar
116. Zhu Y, Yu F, Tan Y, Yuan H, Hu F. Strategies of targeting pathological stroma for enhanced antitumor therapies. Pharmacol. Res. 148, 104401 (2019).
Medline CASGoogle Scholar
117. Schwartzman O, Tanay A. Single-cell epigenomics: techniques and emerging applications. Nat. Rev. Genet. 16(12), 716–726 (2015).
Medline CASGoogle Scholar
118. Lee D-S, Luo C, Zhou J et al. Simultaneous profiling of 3D genome structure and DNA methylation in single human cells. Nat. Methods 62(10), 1–8 (2019).
Google Scholar
119. Kelsey G, Stegle O, Reik W. Single-cell epigenomics: recording the past and predicting the future. Science 358(6359), 69–75 (2017).
Medline CASGoogle Scholar

Vol. 12, No. 2

Metrics

Downloaded 238 times

History

Received 14 June 2019

Accepted 11 November 2019

Published online 18 December 2019

Published in print January 2020

Information

Keywords

Financial & competing interests disclosure

M Sylvestre is a recipient of a fellowship from the Ligue contre le Cancer and the Région Bretagne. K Tarte and D Roulois are supported by the Fondation ARC pour la Recherche sur le Cancer and the INCA PLBIO 17-219, CALYS. D Roulois is supported by La Ligue contre le Cancer and by the Université de Rennes 1 (AAP défis scientifiques). D Roulois is a member of the Réseau Niches et Epigénétiques des Tumeurs from the Cancéropole Grand Ouest. We thank Cancéropôle Grand Ouest to support the Niches and Epigenetics of Tumors network, http://www.canceropole-grandouest.com. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The authors would like to thank A Martin for her comments and proofreading.

PDF download